Trop-2.2 directed radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a pancreatic cancer model | Synapse
March 3, 2026
Trop-2.2 directed radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a pancreatic cancer model
Key Points
Therapeutic benefit was observed in models expressing the trop-2.2 target.
Multiple radiopharmaceutical variants, including 177Lu, 225Ac, and 212Pb, were assessed.
The treatments specifically target the trop-2.2 antigen in pancreatic cancer cells.
Further research may enhance the application of these therapies in clinical settings.
Abstract
Here, we provide several direct and pretargeted radiopharmaceutical variants yielding therapeutic benefit for a Trop-2.2 expressing pancreatic cancer model.